Table 3.
Adverse events reported in >10% of participants
| Arm 1 | Arm 2 | |||
|---|---|---|---|---|
| Body system/Adverse event | ||||
| Total participants with at least one adverse event | Saquinavir/Ritonavir (N = 14) | Saquinavir/Ritonavir + Rifampin (N = 8) | Rifampin (N = 14) | Rifampin + Saquinavir/Ritonavir (N = 9) |
| Transaminase elevation | — | 2 | — | 9 |
| Hepatomegaly | — | 2 | — | 5 |
| Chromaturia | — | — | 9 | — |
| Gastrointestinal disorder | ||||
| Nausea | 4 | — | 1 | 8 |
| Abdominal pain | 2 | 1 | 1 | 4 |
| Vomiting | — | — | — | 4 |
| Flatulence | 1 | 1 | — | 2 |
| Nervous system disorders | ||||
| Headache | — | — | 2 | — |